How to manage <i>Pseudomonas aeruginosa</i> infections.

Détails

Ressource 1Télécharger: 29872449_BIB_91C5DC48B249.pdf (504.47 [Ko])
Etat: Serval
Version: Final published version
Licence: Non spécifiée
ID Serval
serval:BIB_91C5DC48B249
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
How to manage <i>Pseudomonas aeruginosa</i> infections.
Périodique
Drugs in context
Auteur(s)
Bassetti M., Vena A., Croxatto A., Righi E., Guery B.
ISSN
1745-1981 (Print)
ISSN-L
1740-4398
Statut éditorial
Publié
Date de publication
2018
Peer-reviewed
Oui
Volume
7
Pages
212527
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: epublish
Résumé
Infections with <i>Pseudomonas aeruginosa</i> have become a real concern in hospital-acquired infections, especially in critically ill and immunocompromised patients. The major problem leading to high mortality lies in the appearance of drug-resistant strains. Therefore, a vast number of approaches to develop novel anti-infectives is currently pursued. Diverse strategies range from killing (new antibiotics) to disarming (antivirulence) the pathogen. In this review, selected aspects of <i>P. aeruginosa</i> antimicrobial resistance and infection management will be addressed. Many studies have been performed to evaluate the risk factors for resistance and the potential consequences on mortality and attributable mortality. The review also looks at the mechanisms associated with resistance - <i>P. aeruginosa</i> is a pathogen presenting a large genome, and it can develop a large number of factors associated with antibiotic resistance involving almost all classes of antibiotics. Clinical approaches to patients with bacteremia, ventilator-associated pneumonia, urinary tract infections and skin soft tissue infections are discussed. Antibiotic combinations are reviewed as well as an analysis of pharmacokinetic and pharmacodynamic parameters to optimize <i>P. aeruginosa</i> treatment. Limitations of current therapies, the potential for alternative drugs and new therapeutic options are also discussed.
Mots-clé
Pseudomonas aeruginosa, bloodstream infection, ceftazidime-avibactam, ceftolozane-tazobactam, multidrug resistance, new antibiotics, ventilator associated pneumonia
Pubmed
Open Access
Oui
Création de la notice
15/06/2018 17:19
Dernière modification de la notice
29/05/2019 7:09
Données d'usage